knowledge -WSS

knowledge

author：leisure time 2025-09-30 20:35:33 - browse：41

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： The battle over the Brookhaven Landfill on Long Island

Wikipedia

WSS

Death of patient in Alzheimer’s trial raises question of possible risks

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

3 hurdles to bringing medical devices to the U.S. market

The science behind Janet Jackson's pregnancy at 49

What to expect at HLTH 2023, the health care industry conference

In areas with more Black doctors, Black people live longer

knowledge

knowledge

entertainment

Guidelines to prevent youth baseball injuries need more muscle

The strategy behind pharma's lawsuits over drug pricing reform

Medical leaders decry Supreme Court decision on affirmative action

The future of health care in the House

Virginia high school admissions case could be legal follow

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Hepatitis C has a cure — but many Americans still lack access to it

Bristol 'take

focus

FDA rejects Alnylam's heart disease treatment over insufficient data

Analysis of telehealth claims data suggest service duplication

Do masks work? RCTs can't tell us

Cloning humans is technically possible. It's curious no one has tried

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

STAT's guide to the next generation of CAR

entertainment

hotspot

Wikipedia

focus